An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to a study published ...

The familiar sensation of a nosebleed can catch anyone off guard, turning an ordinary moment into a concerning situation.

A new study reveals that individuals with allergic rhinitis and asthma have distinct nasal fungal profiles, hinting at ...

There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...